Công ty CP Dược Phẩm Và Sinh Học Y Tế MEBIPHAR

What Công ty CP Dược Phẩm Và Sinh Học Y Tế MEBIPHAR does

MEBIPHAR (Công ty CP Dược Phẩm Và Sinh Học Y Tế MEBIPHAR) is a Vietnamese pharmaceutical manufacturer and distributor founded in 1988 as Xí nghiệp Vật liệu sinh học MEBIFAC. The Joint Stock Company operates with 27 employees from its headquarters at 31 Ngô Thời Nhiệm, Xuân Hòa ward, Ho Chi Minh City, and manufactures at a GMP-WHO certified facility in the Tan Binh Industrial Zone. As a member company of Aikya Group (Tập đoàn AIKYA), it benefits from group-level assets including an EU-GMP facility in Vinh Long and the E-Pharma Aikya pharmacy management software deployed in partnership with AMIT Group. The company produces prescription medicines, OTC drugs, medical equipment (notably the Mebilook face mask brand), gynecological care products, anti-allergy medications, and health supplements bundled as "Combo sức khỏe." Eleven new products were launched in 2022, two of which achieved national brand equivalence status that same year.

The company's go-to-market combines a nationwide pharmacy distribution channel in Vietnam with a direct-to-consumer e-commerce storefront (MEBIPHAR STORE) and a nascent export business shipping into Yemen and Cambodia. Revenue is generated through one-time product sales across its pharmaceutical and medical device catalog; pricing is not publicly disclosed but positioning emphasizes GMP-WHO certified quality at accessible price points. The customer base is structurally fragmented: individual consumers buying through pharmacies, pharmacy and clinic buyers sourcing medical supplies, and international distributors in two export markets. There is no disclosed public-market listing, no funding rounds in the data, and no enterprise anchor customer — revenue is volume-driven across a long tail of small buyers.

The company's strategic posture under the parent group's 'Energy of Harmony' philosophy combines product expansion (e.g., the 11 new SKUs launched in 2022, 2023 capex plan of over 31 billion VND), international engagement (visits and partnerships with CSPC Pharmaceutical Group, Oman Investment Authority, and AMIT Group in 2025), and community-facing CSR activity (COVID-19 mask and antiviral donations to domestic and regional communities, university partnerships, group events like the Aikya Cross Country Marathon). Leadership transitioned in May 2026 with a newly elected three-member Board of Directors for the 2026-2030 term.

Name

Công ty CP Dược Phẩm Và Sinh Học Y Tế MEBIPHAR

Legal name

Công ty Cổ phần Dược phẩm và Sinh học Y tế MEBIPHAR

Website

https://mebiphar.vn

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

11–50 employees

Short description

MEBIPHAR is a Vietnamese pharmaceutical manufacturer and distributor founded in 1988, operating a GMP-WHO certified facility in Ho Chi Minh City to produce prescription drugs, OTC medicines, medical devices, and the Mebilook face mask brand for retail pharmacies, consumers, and limited export markets in Yemen and Cambodia.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmacies and Drug Retailers (456110)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Full-Line Pharmaceutical Wholesalers (HLAIAJAA), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Pharmaceutical manufacturing
• Prescription medicines
• Medical equipment supplies
• GMP certified drugs
• Health supplements

Headquarters

HQ city

Ho Chi Minh City

HQ country

Vietnam

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: MEBIPHAR manufactures and distributes prescription medicines (tân dược), over-the-counter products, medical equipment, face masks, cosmetics, and health supplements through a nationwide pharmacy network. Products include Combo sức khỏe (health combos), prescribed medicines, medical devices, gynecological washes, and allergy medications.
2. Medical Equipment & Supplies Distribution: Distribution of medical equipment and supplies including face masks (Mebilook brand) and other medical supplies to pharmacies and healthcare facilities.
3. Export Revenue: Begun exporting pharmaceutical products to Yemen and Cambodia as part of international market expansion.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

MEBIPHAR manufactures and distributes pharmaceutical products, including prescription medicines, over-the-counter drugs, medical equipment and supplies, gynecological care products, anti-allergy medications, premium medical face masks under the Mebilook brand, and bundled health combos, from its GMP-WHO certified facility in Ho Chi Minh City. Products are sold to consumers through pharmacies nationwide and the MEBIPHAR STORE online platform, with additional exports to Yemen and Cambodia.

Product overview

MEBIPHAR is a pharmaceutical and medical biotechnology company operating as a member of AIKYA Group. The company manufactures and distributes prescription medicines, medical equipment and supplies, gynecological care products, anti-allergy products, and premium medical face masks (Mebilook brand) through its GMP-WHO certified factory in Ho Chi Minh City. Products are sold through the MEBIPHAR STORE e-commerce platform and a nationwide pharmacy distribution network. MEBIPHAR also participates in AIKY A's digital ecosystem through the E-Pharma Aikya pharmacy management software, which integrates with partner AMIT Group's technology platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Thuốc sức khỏe có kê đơn (Prescription Medicines)

Quantifiable outcome

• 11 new products launched in 2022 contributing to revenue with increasing gross margins
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature3 records

Partnerships

Nine partnerships are on record, tiered minor, major and core.

• Daisy MediaminorGTM or Marketing Partner · 14 October 2025Daisy Media partnered with Aikya Group and AloBacsi on October 14, 2025 for a charitable program 'For beloved Northern Vietnam – Standing together with Thai Nguyen through floods', distributing medicine, medical supplies, and health products to hospitals, health stations, and affected residents.
• AloBacsiminorGTM or Marketing Partner · 14 October 2025AloBacsi partnered with Aikya Group and Daisy Media for the charitable medical outreach program in Thai Nguyen province on October 14, 2025, supporting communities affected by Typhoon No. 11.
• CSPC Pharmaceutical GroupmajorStrategic or Co-development Partner · 11 August 2025CSPC is China's third-largest pharmaceutical company and 30th globally, with market capitalization of USD 15 billion and annual revenue of USD 5 billion. On August 11, 2025, Aikya Group (including MEBIPHAR) welcomed a CSPC delegation at its EU-GMP facility in Vinh Long, exploring strategic cooperation in pharmaceutical manufacturing and technology.
• Đoàn KTQP 737minorGTM or Marketing Partner · 19 June 2025Đoàn KTQP 737 (Military Region 7) partnered with Aikya Group and Công ty Cổ phần Ca cao Intercontinental (CIC) on June 19, 2025 to deliver charitable gifts and medical support to disadvantaged communities in Ia Lop and Ia Rve communes, Ea Sup district, Dak Lak province.
• Công ty Cổ phần Ca cao Intercontinental (CIC)minorGTM or Marketing Partner · 19 June 2025CIC partnered with Aikya Group and Đoàn KTQP 737 on June 19, 2025 for charitable outreach in Ea Sup district, Dak Lak, providing medical supplies and donations to remote border communities.
• AMIT GroupcoreTechnology or Integration · 23 May 2025AIKYA signed a strategic partnership with AMIT Group on May 23, 2025 to deploy E-Pharma Aikya pharmacy management software nationwide. The software provides automated invoice scanning, retail invoicing per Decree 70/2025/NĐ-CP, national pharmaceutical database integration, tax authority connectivity, expiry warnings, and remote pharmacy monitoring.
• Tập đoàn AIKYAcoreStrategic or Co-development PartnerMEBIPHAR is a member company of Aikya Group (Tập đoàn AIKYA), operating under the 'Energy of Harmony' philosophy. The group encompasses multiple pharmaceutical companies and shares resources, strategy, and brand identity. MEBIPHAR benefits from group synergies including R&D capabilities, international partnerships, and the Aikya ecosystem including E-Pharma software.
• Công ty Cổ phần Dược phẩm TV.PHARMcoreStrategic or Co-development PartnerTV.PHARM is a member company within the Aikya Group ecosystem, collaborating with MEBIPHAR on community health initiatives including COVID-19 mask donations and charitable medical supply distributions.
• Trường Đại học Y Dược TP.HCMminorStrategic or Co-development PartnerOn April 20, 2025, MEBIPHAR participated in the university admission counseling event organized by the Faculty of Pharmacy at University of Medicine and Pharmacy Ho Chi Minh City, engaging with high school students and promoting careers in pharmacy.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• CSPC Pharmaceutical Group: China's third-largest pharma company (~$15B market cap) that recently visited Aikya/MEBIPHAR facilities for strategic cooperation. Comparable as a large-scale GMP manufacturer with technology-transfer and partnership capacity relevant to MEBIPHAR's growth ambitions.
• Sanofi Vietnam: Multinational pharmaceutical incumbent operating in Vietnam across prescription and consumer health. Competes with MEBIPHAR in the broader pharmacy-channel branded pharma space, particularly for OTC and allergy categories.

Direct peers

• OPC Pharmaceutical JSC: Vietnamese pharma manufacturer focused on OTC, supplements, and consumer health products. Comparable to MEBIPHAR in pharmacy-channel distribution and consumer health positioning.
• Pymepharco JSC: Vietnamese pharmaceutical manufacturer with both branded generics and licensed-in products, sold through pharmacy networks. Direct peer to MEBIPHAR in domestic GMP-certified manufacturing and distribution.
• Imexpharm Corporation: Vietnamese manufacturer of branded generics (antibiotics, cardiovascular, etc.) sold through domestic pharmacy channels. Direct peer given shared GMP manufacturing model and prescription-drug focus.
• Hatay Pharmaceutical JSC: Vietnamese pharmaceutical manufacturer with GMP-certified production and nationwide pharmacy distribution. Closely comparable domestic peer to MEBIPHAR in scale and product mix.
• DHG Pharmaceutical JSC: One of Vietnam's largest listed pharmaceutical manufacturers with broad prescription, OTC, and consumer health portfolios. Direct competitor to MEBIPHAR in the domestic branded pharma and pharmacy distribution space.
• Traphaco JSC: Leading Vietnamese pharma company specializing in branded generic and traditional medicine products distributed through nationwide pharmacy networks. Closely comparable to MEBIPHAR in business model and channel strategy.
• Binh Dinh Pharmaceutical & Medical Equipment JSC (Bidiphar): Vietnamese pharma manufacturer producing Western and traditional medicines for domestic pharmacy distribution. Similar scale and product breadth as MEBIPHAR's branded portfolio.
• TV.PHARM: Sibling company within the Aikya Group ecosystem, also manufacturing pharmaceuticals and co-participating in COVID-19 relief and community health initiatives. Highly comparable operating model and channel footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/mebiphar
• TikToktiktok.com/@mebiphar
• LinkedInlinkedin.com/company/mebiphar

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Công ty CP Dược Phẩm Và Sinh Học Y Tế MEBIPHAR